|
Market Closed -
Other stock markets
|
Pre-market 01:00:00 | |||
| 770.64 USD | +1.04% |
|
774.50 | +0.50% |
| 06-23 | Amgen experimental weight-loss drug needs lower dose to limit side effects | RE |
| 06-23 | Wall St rallies as rate cut hopes outweigh Middle East turmoil | RE |
| Capitalization | 685B 592B 556B 507B 940B 59,092B 1,061B 6,568B 2,525B 27,122B 2,569B 2,514B 100,070B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 710B 613B 576B 525B 974B 61,231B 1,099B 6,806B 2,617B 28,104B 2,662B 2,605B 103,692B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
99.81% | Yield 2025 * |
0.78% | Yield 2026 * | 0.87% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.32% | ||
| 1 week | -5.95% | ||
| Current month | +4.47% | ||
| 1 month | +7.75% | ||
| 3 months | -7.99% | ||
| 6 months | +0.38% | ||
| Current year | -0.18% |
| 1 week | 755.56 |  | 805.16 |
| 1 month | 714.33 | | 825 |
| Current year | 677.09 | | 935.62 |
| 1 year | 677.09 | | 972.53 |
| 3 years | 296.32 | | 972.53 |
| 5 years | 129.21 | | 972.53 |
| 10 years | 64.18 | | 972.53 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 31/12/2016 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 08/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 31/12/2004 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 31/03/2009 |
| Director/Board Member | 53 | 11/12/2011 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 6.49% | 21 M€ | -0.24% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.04% | -5.95% | -12.81% | +151.28% | 685B | ||
| +1.02% | -3.68% | +1.73% | -13.90% | 360B | ||
| -0.83% | -3.83% | +7.85% | +24.53% | 327B | ||
| -5.29% | -12.70% | -54.38% | +18.36% | 326B | ||
| +0.46% | -3.41% | +3.05% | -14.83% | 255B | ||
| +0.20% | -2.14% | +1.16% | +21.00% | 228B | ||
| +0.27% | -5.15% | -16.45% | +1.13% | 217B | ||
| +1.39% | -1.90% | -38.68% | -10.09% | 199B | ||
| -5.84% | -7.72% | -11.59% | +13.45% | 156B | ||
| +0.25% | -2.08% | -13.37% | -51.03% | 136B | ||
| Average | -0.78% | -4.16% | -13.35% | +13.99% | 288.83B | |
| Weighted average by Cap. | -0.53% | -4.82% | -12.87% | +37.04% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | - | - |
| Net Debt | 24.79B 21.41B 20.12B 18.34B 34.03B 2,139B 38.39B 238B 91.41B 982B 92.99B 91.01B 3,622B | 12.19B 10.53B 9.89B 9.02B 16.73B 1,052B 18.88B 117B 44.94B 483B 45.72B 44.75B 1,781B |
More financial data
* Estimated data
Employees
47,000
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/06/25 | 770.64 $ | +1.04% | 3,948,954 |
| 20/06/25 | 762.73 $ | -2.84% | 6,210,647 |
| 18/06/25 | 785.03 $ | -0.78% | 2,442,938 |
| 17/06/25 | 791.24 $ | -2.02% | 2,875,634 |
Delayed Quote Nyse, June 23, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
Number of Analysts
0
Last Close Price
770.64
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition